Literature DB >> 11716889

beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure.

D J Campbell, A Aggarwal, M Esler, D Kaye.   

Abstract

Blood concentrations of angiotensin II are often raised in patients with heart failure, despite treatment with angiotensin-converting-enzyme (ACE) inhibitors. We compared concentrations of angiotensin II in two groups of matched patients, receiving ACE inhibitor therapy with or without concomitant administration of beta-blockers. Concentrations of angiotensin II were lower in individuals taking beta-blockers than in those who were not (geometric mean 1.1 [95% CI 0.4-2.7] vs 15.5 [4.6-52.6] fmol/mL, 95% CI for difference 3-59). Our findings indicate that a reduction in angiotensin II concentrations might contribute to the therapeutic benefits of beta-blockade in heart failure, especially in patients who simultaneously receive ACE inhibitor treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11716889     DOI: 10.1016/S0140-6736(01)06660-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

Review 1.  Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly.

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2008-02-07       Impact factor: 4.214

Review 2.  Now that we have a direct renin inhibitor, what should we do with it?

Authors:  Alice Stanton
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

3.  Bone marrow-derived cells contribute to fibrosis in the chronically failing heart.

Authors:  Po-Yin Chu; Justin Mariani; Samara Finch; Julie R McMullen; Junichi Sadoshima; Tanneale Marshall; David M Kaye
Journal:  Am J Pathol       Date:  2010-02-11       Impact factor: 4.307

Review 4.  Pharmacological management of chronic heart failure in adults: a review of the literature.

Authors:  Richard Auty
Journal:  Malawi Med J       Date:  2004-03       Impact factor: 0.875

Review 5.  Genomic variation and neurohormonal intervention in heart failure.

Authors:  Dennis M McNamara
Journal:  Heart Fail Clin       Date:  2010-01       Impact factor: 3.179

Review 6.  How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?

Authors:  Marc S Weinberg; Nicholas Kaperonis; George L Bakris
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

Review 7.  Interactions between the sympathetic nervous system and the RAAS in heart failure.

Authors:  Steven R Goldsmith
Journal:  Curr Heart Fail Rep       Date:  2004-07

Review 8.  Valsartan in the treatment of heart attack survivors.

Authors:  Bodh I Jugdutt
Journal:  Vasc Health Risk Manag       Date:  2006

Review 9.  Bioactive Carbohydrates and Peptides in Foods: An Overview of Sources, Downstream Processing Steps and Associated Bioactivities.

Authors:  Maria Hayes; Brijesh K Tiwari
Journal:  Int J Mol Sci       Date:  2015-09-17       Impact factor: 5.923

10.  Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results.

Authors:  Marco Metra; Savina Nodari; Tania Bordonali; Patrizia Milani; Carlo Lombardi; Silvia Bugatti; Benedetta Fontanella; Giulia Verzura; Rossella Danesi; Livio Dei Cas
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.